ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07735
0,41%
Bitcoin
62.886,16
6,37%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. NeuroBo Pharmaceuticals Inc (NRBO)

  7. NeuroBo Pharmaceuticals Inc (NRBO) News

NRBO

NeuroBo Pharmaceuticals (NRBO)

NeuroBo Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NRBO
DatumZeitQuelleÜberschriftSymbolFirma
30/04/202414h01PR Newswire (US)NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in JuneNASDAQ:NRBONeuroBo Pharmaceuticals Inc
17/04/202414h05PR Newswire (US)NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/04/202414h01PR Newswire (US)NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
28/03/202413h01PR Newswire (US)NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/03/202413h01PR Newswire (US)NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
04/03/202414h01PR Newswire (US)NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerNASDAQ:NRBONeuroBo Pharmaceuticals Inc
04/03/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
29/02/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
29/02/202414h01PR Newswire (US)NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
14/02/202414h52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
12/02/202414h01PR Newswire (US)NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor ConferenceNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/02/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/02/202414h01PR Newswire (US)NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
18/01/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
18/01/202414h01PR Newswire (US)NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
09/01/202414h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
09/01/202414h30PR Newswire (US)NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price RequirementNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/01/202414h01PR Newswire (US)NeuroBo to Participate in Industry and Investor Conferences in JanuaryNASDAQ:NRBONeuroBo Pharmaceuticals Inc
28/12/202315h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
28/12/202314h45PR Newswire (US)NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
19/12/202315h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
19/12/202314h43PR Newswire (US)NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/12/202315h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/12/202314h31PR Newswire (US)NeuroBo to Participate in Investor Conferences in DecemberNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/11/202322h29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/11/202322h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/11/202322h05PR Newswire (US)NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/11/202314h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/11/202314h05PR Newswire (US)NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.NASDAQ:NRBONeuroBo Pharmaceuticals Inc
30/10/202313h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:NRBO

Kürzlich von Ihnen besucht

USOTC
BNPQY
BNP Paribas (QX)
TG
BAYN
Bayer
TG
LHA
Deutsche Lufthansa
AMEX
XLV
Health Care Select Sector
AMEX
XLE
Energy Select Sector SPDR
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
TG
DTE
Deutsche Telekom
FX
EURUSD
Euro vs US Dollar
TG
BAS
BASF
NASDAQ
TSLA
Tesla
DBI
MDAX
MDAX
TG
TUI1
Tui
AMEX
SPY
SPDR S&P 500
USOTC
ADDYY
Adidas (QX)
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten